Ongoing trials in Africa

Right now there are six approved or ongoing HIV vaccine trials in Africa. All of the current trials are early safety studies (called Phase I or Phase I/II). Such trials usually enroll less than 100 volunteers and monitor them for any side effects or negative reactions. These studies will not provide information about whether the vaccine protects against HIV. Larger trials (Phase III) are needed—usually with thousands of volunteers—to find out whether a vaccine can protect against HIV. Phase III trials are carried out once vaccine safety has been established.

The list below shows approved and ongoing African vaccine trials:

• BOTSWANA:
  VACCINE (CLADE): EP HIV-1090 DNA (B)
  SITES: Botswana (2), US (1)
  TRIAL SPONSORS; MANUFACTURER: HVTN; Epimmune (US)
  STATUS: Ongoing
• KENYA:
  VACCINE (CLADE): HIVA.DNA and/or HIVA.MVA (A)
  SITES: Kenya (1), UK (1)
  TRIAL SPONSORS; MANUFACTURER: IAVI, Kenyan AIDS Vaccine Initiative Medical Research Council (UK); Cobra/IDT
  STATUS: Ongoing
   
  VACCINE (CLADE): HIVA.MVA (A)
  SITES: Kenya (1)
  TRIAL SPONSORS; MANUFACTURER: IAVI, Kenyan AIDS Vaccine Initiative, Medical Research Council (UK); Cobra/IDT
  STATUS: Ongoing
• SOUTH AFRICA:
  VACCINE (CLADE): AVX101 (C)
  SITES: South Africa (2), US (4)
  TRIAL SPONSORS; MANUFACTURER: HVTN; AlphaVax
  STATUS: Approved
   
  VACCINE (CLADE): HIVA.MVA (A)
  SITES: South Africa (2), Europe
  TRIAL SPONSORS; MANUFACTURER: IAVI; Cobra/IDT
  STATUS: Approved
• UGANDA:
  VACCINE (CLADE): HIVA.DNA and/or HIVA.MVA (A)
  SITES: Uganda (1)
  TRIAL SPONSORS; MANUFACTURER: IAVI, Uganda Virus Research Institute; Cobra/IDT
  STATUS: Ongoing